Daiichi Sankyo, AstraZeneca’s ENHERTU gets BTD for HER2 Low Metastatic Breast Cancer
This treatment is meant for patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer patients who have earlier received a systemic therapy in